NIH’s Policy Shift on Fetal Tissue Research

Recent statements from the National Institutes of Health (NIH) about halting federal funding for research involving tissue from elective abortions may seem like just another political maneuver coinciding with the anniversary of the 1973 Supreme Court decision on abortion. However, that’s overlooking a more significant aspect of NIH Director Jay Bhattacharya’s remarks concerning the agency’s push to embrace modern biomedical science.

On January 22, Bhattacharya noted, “NIH is pushing American biomedical science into the 21st century. This decision is about advancing science by investing in breakthrough technologies more capable of modeling human health and disease. Under President Trump’s leadership, taxpayer-funded research must reflect the best science of today and the values of the American people.”

The announcement also indicated that NIH aims to evaluate more areas where modernization could hasten progress, engaging the scientific community to identify emerging technologies that could lessen reliance on outdated research practices.

This raises questions: Is NIH covering up an ideological choice that might hinder scientific progress and delay the discovery of cures for diseases? The historical context suggests otherwise.

Researchers have long claimed that fetal tissue from elective abortions is essential for disease research and developing therapies, as well as studying human development. This has been a point of contention for years. Yet, despite over a century of research involving fetal tissue, no cures have been found, and results from such studies often lack clarity, even in basic biology.

In the U.S., the regulation of human fetal tissue research has been inconsistent at best.

A similar executive order was issued by President Bill Clinton on January 22, 1993, focused on funding transplantation studies. Yet, the large-scale NIH-funded studies that followed reportedly led to significant side effects for patients.

No clinical trials using fetal tissue have received support since 2005. The Ethics Advisory Board, set up by Trump’s first administration in 2020 to review fetal tissue research proposals, mostly rejected them due to ethical concerns. Their report highlighted that even proponents of this research recognized significant ethical dilemmas, with a good portion of the votes being unanimous or nearly so against funding.

Public sentiment took a notable turn when many Americans declined COVID-19 vaccines due to ethical objections related to fetal tissue. Instead of mandates from the Biden administration, addressing these concerns and creating vaccines using non-fetal cells—technologies that already exist—might have built more trust in the pharmaceutical industry and encouraged wider vaccination.

The new NIH policy reflects a thoughtful integration of ethics and efficiency, aiming to allocate taxpayer dollars towards research avenues that hold significant potential.

A comprehensive review of the history, science, and ethics surrounding fetal tissue research was conducted by members of the Science Alliance for Life and Technology (SALT). This group has long sought to highlight the failures associated with human fetal tissue research while advocating for modern, ethical alternatives such as adult stem cells, organoids, ethically sourced tissues, direct reprogramming, and gene-edited cells.

Some breakthrough technologies worth exploring include:

• Sickle cell anemia affects around 100,000 patients in the U.S. and 20 million worldwide, causing severe health issues and early death. However, recent advancements like cord blood stem cell transplants and newly approved gene therapies have successfully treated sickle cell disease, alleviating suffering for many.
• Scientists have used “direct reprogramming” techniques to convert skin cells into retinal cells, restoring sight in mice. While still experimental, this method shows promise for treating various conditions.
• Another patient has been reported as “cured” of HIV following a specific adult stem cell transplant, revealing potential for wider donor acceptance and pathways for gene-edited cell use in transplants.
• Humanized mice developed from aborted fetal tissue face both ethical and scientific challenges, making them less suitable for advancing human immunotherapy or vaccine development. However, researchers have generated humanized mice using cord blood stem cells and discarded surgical tissues, achieving clinically relevant results.
• Gene therapies for genetic conditions are gaining traction, with noteworthy advancements highlighted by personalized treatments like the one for Baby KJ, showcasing the future of innovative genetic therapies.
• Companies are also emerging to screen for rare genetic diseases and develop treatments. This investment in early detection and innovative therapies can bring hope to patients and families while driving national health and innovation efforts.

The newly implemented NIH policy is a significant stride toward modernizing scientific research and ensuring responsible use of taxpayer resources. It’s something that many can appreciate.